List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
Image-based phenotypic profiling of small molecules has been used for identification and characterisation of small molecules in drug discovery and can provide important insights into their mechanisms of action (MOA). This article discusses the use of phenotypic profiling in drug discovery and how machine-learning algorithms could help improve objectivity, processing…
Typically, early drug discovery campaigns start with the screening of chemical libraries to identify candidate chemotypes modulating a particular target and/or phenotype. Success of the primary screening depends on multiple factors related to both biology and chemistry. These include the target’s druggability, sensitivity and specificity of assay system, composition and…
Integrating hardware, software and fluorescent labels for optimised HCA assay development.
Introducing the CellInsight CX7 LZR High-Content Analysis Platform - an updated version of our CellInsight CX7 instrument with advanced laser technology.
From the B-27 Plus Neuronal Culture System to fluorescent probes for cell analysis. Publication history of B-27 supplements demonstrates that researchers are expanding its use, far beyond the long-term culture of rat hippocampal and cortical neurons.
Researchers have developed a method that could drastically accelerate the search for new drugs to treat mental health disorders.
HCA platforms automate image capture and data analysis, giving researchers the sample sizes and precise quantitation tools required for research.
By the 1890s William B. Coley had injected streptococcal organisms in patients with solid tumours (“Coley’s Toxins”) to activate the immune system. Coley (1862-1936) was an American bone surgeon and pioneer of cancer immunotherapy. He was convinced that post-surgical infections had helped patients to recover better from their cancer by…
Osteoarthritis (OA) is a painful and debilitating disease of articular joints.1,2 Its clinical prevalence is as high as 21.6 percent of the population in the United States,3 which constitutes direct health costs of over 80 billion US dollars annually.4
Flow chemistry is on the rise thanks to the commercial availability of benchtop continuous flow systems that has driven widespread adoption of the technique across a broad range of applications in both academia and industry. In particular, flow chemistry is delivering significant benefits in the area of drug discovery and…
Vaccination with as few as four tumour antigens generated antigen-specific responses, reduced intestinal tumours, and improved survival in a mouse model of Lynch syndrome...
Over the past 30 years, one strategy the pharmaceutical industry has adopted in the drug discovery process has been to “fail early, fail often”.1,2 As most molecules in the early stages of drug discovery will have sub-optimal characteristics, significant modification is necessary to improve their properties.
A method to view the immune cell 'landscape' of bowel cancer tumours could pave the way towards more individualised medicine and treatment...
Current technologies that measure molecular interactions for drug discovery slow down and complicate screening. Dianthus is the answer to the demands for fast, non-stop, highly sensitive hit identification, hit validation and lead optimisation.
Data drives drug discovery, yet it continues to be among the biggest challenges faced by the industry.1 Experiments are often not repeatable and data interpretation is subject to the biases and limitations of human beings.
